We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Martin
Turner
martin.turner@ndcn.ox.ac.uk
Prof
Martin
Turner
martin.turner@ndcn.ox.ac.uk
Systemic atrophies primarily affecting the central nervous system
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
This project creates an invaluable resource of biological samples taken at intervals from MND patients across three leading UK research centres. This will greatly help the much-needed development of specific markers of disease activity, called biomarkers. It will also provide nerve cell models to test future treatments. There is no single test for MND and diagnosis relies on the opinion of an expert neurologist. Although MND is currently incurable, there is great variation in the speed of progression of symptoms. There is no easy way to monitor disease activity other than testing muscle strength or measuring overall survival. The cause of some cases of MND is more strongly related to a person’s genetic code than others. All of this variation makes testing the effectiveness of new drugs in people living with MND very difficult, and it currently requires long and complicated clinical trials. Biomarkers include chemicals measured in blood, urine or spinal fluid samples, which might be used to speed up diagnosis before the person develops major disability. In clinical trials, such biomarkers can be used to group patients together with similar disease sub-types and rates of progression, and to provide an earlier answer on whether a new treatment is working or not. A small skin sample from a person living with MND can be used to grow personalised motor nerve cells in a laboratory dish that can be used to test new drug treatments. This project provides a pipeline to collect a large number of samples from a range of people living with MND at several points in their disease, which will accelerate biomarker development and new drug testing towards a world free of MND.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
The participant may not enter the study if ANY of the following apply: • Age < 18 years • Pregnancy or any other condition that in the opinion of the investigator could interfere with the interpretation of the study results. In addition to the general inclusion/exclusion criteria described above, the additional exclusion criteria apply for invasive procedures (skin biopsy and lumbar puncture): • Significant bleeding diathesis or sepsis, or other condition that in the opinion of the investigator could constitute a health risk to the participant if he/she took part in this element of the study.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Oxford and funded by Motor Neurone Disease Association (MNDA) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 31877
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
